Tag: Clinical

Gene editing for recessive dystrophic epidermolysis bullosa: A little bit closer to clinical applications

A group of researchers from the Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) (Biomedical Research Networking Centre on Rare Diseases), Universidad Carlos III de Madrid (UC3M), the Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT) (Research Center for Energy, Environmental and Technology), and the Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD)

Siemens, SAS join forces for AI-enabled IoT analytics

Siemens and SAS are partnering up for an artificial project that will develop new analytics for cloud and edge computing, combining SAS’ open source streaming analytics through Siemens’ MindSphere IoT platform. It’s one of two big AI partnerships announced this week by Siemens, whose Healthineers division is also working with Intel on a cardiac MRI

EmblemHealth works with physician group to deploy HealthReveal clinical AI tool within Epic EHR

EmblemHealth and its subsidiary AdvantageCare Physicians in New York announced that they are integrating a clinical artificial intelligence tool made by startup HealthReveal into ACPNY’s Epic electronic health record. HOW IT WORKS HealthReveal’s aim is to address a basic question, HealthReveal CEO Dr. Lonny Reisman told Healthcare IT News: “Is the patient actually getting the right

New study identifies top 11 clinical decision support vendors

Seventy-four percent of healthcare provider organizations use clinical decision support technology, according to a new study from Reaction Data relying on CDS to make more informed medication orders (30 percent), lab orders (24 percent), medical imaging orders (20 percent), choosing wisely (13 percent) and other (13 percent). The report polled interviewed 180 clinical, quality and

Early-stage clinical trial of antimalarial drug begins

Enrollment has begun in a Phase 1 clinical trial to test the safety of a new investigational drug designed to treat malaria, as well as its effect on the human body. The first-in-human study is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and

Mercy Health earns HIMSS Davies Award for innovative approach to opioid fight

Mercy Health earned a 2018 HIMSS Davies Award of Excellence for its work in using health IT to help treat the opioid epidemic. The award recognizes outstanding achievement of organizations that have used health information technology to substantially improve patient outcomes and value, and spotlights organizations promoting health information and technology-enabled improvements in patient and

AMP addresses clinical relevance of DNA variants in chronic myeloid neoplasms

The Association for Molecular Pathology (AMP), the premier global molecular diagnostics professional society, today published consensus, evidence-based recommendations to aid clinical laboratory professionals with the management of most Chronic Myeloid Neoplasms (CMNs) and development of high-throughput pan-myeloid sequencing testing panels. The report, “Clinical Significance of DNA Variants in Chronic Myeloid Neoplasms (CMNs): A Report of

NIH begins clinical trial of live, attenuated Zika vaccine

Vaccinations have begun in a first-in-human trial of an experimental live, attenuated Zika virus vaccine developed by scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The trial will enroll a total of 28 healthy, non-pregnant adults ages 18 to 50 at the Johns Hopkins Bloomberg

Few receive all high-priority clinical preventive services

(HealthDay)—Only 8 percent of U.S. adults aged 35 years and older receive all high-priority clinical preventive services, according to a report published in the June issue of Health Affairs. Amanda Borsky, Dr.P.H., from the Agency for Healthcare Research and Quality in Rockville, Md., and colleagues examined receipt of 15 high-priority clinical preventive services among 2,186

New study reveals how electronic health records can benefit clinical trials

The study entitled “Long term extension of a randomised controlled trial of probiotics using electronic health records” led by researchers in the Swansea University Medical School and the College of Human and Health Sciences, was published in Scientific Reports. The findings demonstrate the potential of using anonymised routinely collected electronic health records, such as those

Tips for doing DIY predictive analytics right

Michael Johnson, a decision support data scientist at Bend, Oregon-based St. Charles Health System, has only worked in healthcare for a couple years. Before that, he'd spent most of his career doing data modeling and predictive analytics in higher education and in the military. During his short time so far in this data-intensive industry, Johnson,

Not enough women included in some heart disease clinical trials

Women are underrepresented in clinical trials for heart failure, coronary artery disease and acute coronary syndrome but proportionately or overrepresented in trials for hypertension, atrial fibrillation and pulmonary arterial hypertension, when compared to incidence or prevalence of women within each disease population, according to a study in the Journal of the American College of Cardiology.

Geisinger injects machine learning into clinical workflow to find health problems faster

Geisinger doctors and researchers have trained computers to read CT scans of patients’ heads to detect a life-threatening form of internal bleeding called intracranial hemorrhage. Because early and accurate diagnosis is critical, leading hospitals are moving forward with precision medicine tactics built on artificial intelligence and machine learning technologies. Last week, for instance, Intermountain-owned Navican

Geisinger execs: DNA sequencing program saving patient lives

Geisinger Health System CEO David Fineberg, MD, and other top executives said Geisinger’s gene sequencing program is helping to better project adverse health issues in the short-term and the hospital is expecting even better results to come. Geisinger’s DNA sequencing project has the potential to identify virtually everyone in its patient population to pinpoint increased

RB1 gene mutations underlie clinical resistance to CDK 4/6 inhibitor breast cancer therapy

A multi-institutional research team has identified what may be a novel mechanism underlying acquired resistance to CDK 4/6 inhibitor treatment for breast cancer. In their report published in the Annals of Oncology, the team—led by investigators at Massachusetts General Hospital (MGH), Institute Gustave Roussy in Paris, and Texas Oncology-Baylor Sammons Cancer Center/U.S. Oncology in Dallas—reports